 |
0 Diseases |  |
24 Trials |
|
24 Trials |  |
921 News |  |
| «12345678910111213...1920» |
- ||||||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion, Trial primary completion date, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice (clinicaltrials.gov) - Dec 26, 2023
P=N/A, N=458, Completed, Sponsor: Novo Nordisk A/S
Enrolling by invitation --> Completed | Trial primary completion date: Mar 2023 --> Nov 2023
- Rybelsus (semaglutide oral) / Novo Nordisk
Semaglutide-loaded lipid nanocapsules effect on metabolic dysfunction-associated steatotic liver (Teun - Hilton Antwerp Old Town) - Dec 19, 2023 - Abstract #BWG2024BWG_68;
Conclusions The results show a higher impact on the metabolic syndrome associated with MASLD and reduced inflammation partially mitigating this way the progression of the disease. Although resolution of MASLD was not achieved, the oral administration of the nanosystem was more efficient at preventing the progression of the disease into more severe states when compared to the orally marketed version of semaglutide, Rybelsus, when administered as a suspension.
- | Mounjaro (tirzepatide) / Eli Lilly
Review, Journal: Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus. (Pubmed Central) - Dec 17, 2023
Among Japanese patients with T2D, tirzepatide showed the greatest effectiveness in reducing HbA1c levels and inducing weight loss. The study provides evidence to guide GLP-1RA treatment strategies in Japanese patients with T2D.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double-Blind Single-Centre Study. (Pubmed Central) - Dec 13, 2023
The study supports the efficacy of swallow balloon therapy combined with semaglutide oral formulation in promoting weight loss and improving comorbid conditions. The findings highlight the potential of this combined approach in managing obesity and its associated health issues.
- ||||||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice (clinicaltrials.gov) - Dec 12, 2023
P=N/A, N=99, Completed, Sponsor: Novo Nordisk A/S
The findings highlight the potential of this combined approach in managing obesity and its associated health issues. Active, not recruiting --> Completed | N=194 --> 99 | Trial completion date: Dec 2023 --> May 2023 | Trial primary completion date: Dec 2023 --> May 2023
- | Rybelsus (semaglutide oral) / Novo Nordisk
Trial initiation date: Clinical Trial of Rybelsus (semaglutide) Among Adults with Alcohol Use Disorder (AUD) (clinicaltrials.gov) - Nov 30, 2023
P2, N=135, Recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed | N=194 --> 99 | Trial completion date: Dec 2023 --> May 2023 | Trial primary completion date: Dec 2023 --> May 2023 Initiation date: Aug 2023 --> Dec 2023
- | Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: TEAL: Treating PCOS With Semaglutide vs Active Lifestyle Intervention (clinicaltrials.gov) - Nov 27, 2023
P2/3, N=60, Active, not recruiting, Sponsor: University of Colorado, Denver
Initiation date: Aug 2023 --> Dec 2023 Recruiting --> Active, not recruiting
- | Journal: In brief: GI effects of GLP-1 receptor agonists. (Pubmed Central) - Nov 24, 2023
Recruiting --> Active, not recruiting No abstract available
- |||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice (clinicaltrials.gov) - Nov 22, 2023
P=N/A, N=462, Recruiting, Sponsor: Novo Nordisk A/S
No abstract available Trial primary completion date: Oct 2023 --> May 2024
- ||||||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice (clinicaltrials.gov) - Nov 22, 2023
P=N/A, N=336, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: Oct 2023 --> May 2024 Enrolling by invitation --> Completed
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Efficacy, safety, and patient satisfaction with oral semaglutide: first single-centre clinical experience. (Pubmed Central) - Nov 21, 2023
Oral semaglutide, the first oral glucagon-like peptide 1 receptor agonist, was effective and safe, and associated with high patient satisfaction, in its first recipients in Slovenia. The results are important for daily clinical practice involving patients with type 2 diabetes, however, due to the small study population, lack of placebo control, and short exposure to oral semaglutide, the effectiveness of oral semaglutide in clinical practice requires further investigation.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: Sema-Lit: Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus (clinicaltrials.gov) - Nov 18, 2023
P=N/A, N=50, Recruiting, Sponsor: Medanta, The Medicity, India
The results are important for daily clinical practice involving patients with type 2 diabetes, however, due to the small study population, lack of placebo control, and short exposure to oral semaglutide, the effectiveness of oral semaglutide in clinical practice requires further investigation. Not yet recruiting --> Recruiting
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal, HEOR: Budget impact of introducing oral semaglutide to the public healthcare benefit package in Saudi Arabia. (Pubmed Central) - Nov 11, 2023
The price difference is offset by positive health outcomes and costs. This conclusion was confirmed through a probabilistic sensitivity analysis.
- | Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Implications of Ozempic (Pubmed Central) - Nov 3, 2023
Discontinuation of Ozempic should be considered prior to general anesthesia due to gastrointestinal side effects including delayed gastric emptying. As the popularity of Ozempic grows, facial plastic surgeons must be aware of both the impact on facial appearance and perioperative considerations.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date, Real-world evidence, Real-world: NN9924-4645: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice (clinicaltrials.gov) - Nov 2, 2023
P=N/A, N=194, Recruiting, Sponsor: Novo Nordisk A/S
As the popularity of Ozempic grows, facial plastic surgeons must be aware of both the impact on facial appearance and perioperative considerations. Trial primary completion date: Sep 2023 --> May 2024
- || Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice (clinicaltrials.gov) - Nov 2, 2023
P=N/A, N=194, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Trial primary completion date: Sep 2023 --> May 2024 Trial primary completion date: Aug 2023 --> Sep 2024
- || Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date: A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants (clinicaltrials.gov) - Nov 1, 2023
P1, N=260, Recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Aug 2023 --> Sep 2024 Trial primary completion date: Jul 2023 --> Feb 2024
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait (clinicaltrials.gov) - Nov 1, 2023
P=N/A, N=288, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: Jul 2023 --> Feb 2024 Enrolling by invitation --> Completed
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Switching from subcutaneous to oral semaglutide in type 2 diabetes: A prospective study. (Pubmed Central) - Oct 30, 2023
Enrolling by invitation --> Completed No abstract available
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III (clinicaltrials.gov) - Oct 23, 2023
P1, N=120, Recruiting, Sponsor: Novo Nordisk A/S
- |||||| orforglipron (OWL833) / Eli Lilly
Enrollment open: ACHIEVE-3: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin (clinicaltrials.gov) - Oct 19, 2023
P3, N=1576, Recruiting, Sponsor: Eli Lilly and Company
No abstract available Not yet recruiting --> Recruiting
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk
New P3 trial: NN9924-7663: Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes (clinicaltrials.gov) - Oct 15, 2023
P3, N=912, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | New trial: Steno1: Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes (clinicaltrials.gov) - Oct 13, 2023
P=N/A, N=2000, Not yet recruiting, Sponsor: Steno Diabetes Center Copenhagen
- |||||| lotiglipron (PF-07081532) / Pfizer
Trial termination: Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity (clinicaltrials.gov) - Oct 12, 2023
P2, N=902, Terminated, Sponsor: Pfizer
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; The decision to terminate clinical development of PF-07081532 is based on pharmacokinetic data from Phase 1 drug-drug-interaction studies and laboratory measurements of elevated transaminases in these Phase 1 studies as well as a Phase 2 study.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study. (Pubmed Central) - Oct 6, 2023
Finally, an overall improvement in body fluid distribution was observed. Our real-world data confirm the clinical efficacy of oral semaglutide and highlight its ability to improve the nutritional status of patients with T2D.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy. (Pubmed Central) - Oct 5, 2023
P3
Our real-world data confirm the clinical efficacy of oral semaglutide and highlight its ability to improve the nutritional status of patients with T2D. Immediate oral semaglutide is likely to represent a cost-effective treatment in people with type 2 diabetes with inadequate glycaemic control on metformin plus an SGLT-2 inhibitor in the UK.
- | Rybelsus (semaglutide oral) / Novo Nordisk
New trial: Sema-Lit: Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus (clinicaltrials.gov) - Sep 29, 2023
P=N/A, N=50, Not yet recruiting, Sponsor: Medanta, The Medicity, India
- | Rybelsus (semaglutide oral) / Novo Nordisk
Retrospective data, Journal, Real-world evidence, Real-world: Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes. (Pubmed Central) - Sep 28, 2023
Oral semaglutide was well tolerated. (4) This study shows that in the real-world setting, oral semaglutide is effective and safe as a switchover or as an add-on therapy for the treatment of T2DM.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Boosting systemic absorption of peptides with a bioinspired buccal-stretching patch. (Pubmed Central) - Sep 27, 2023
Moreover, systemic exposure comparable to that of the approved oral semaglutide tablet was achieved without further optimization. Last, a first-in-human study involving 40 healthy participants confirmed the dosage form's acceptability, thereby supporting the clinical translatability of this simple yet effective platform technology.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal, Real-world evidence, Real-world: Real-World Hemoglobin A1c Changes, Prescribing Provider Types, and Medication Dose Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide. (Pubmed Central) - Sep 23, 2023
Last, a first-in-human study involving 40 healthy participants confirmed the dosage form's acceptability, thereby supporting the clinical translatability of this simple yet effective platform technology. Patients with T2DM in this study experienced significant reductions in HbA1c within 6
- | Rybelsus (semaglutide oral) / Novo Nordisk
New P2 trial: The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial (clinicaltrials.gov) - Sep 22, 2023
P2, N=64, Not yet recruiting, Sponsor: Odense University Hospital
- |||||||||| orforglipron (OWL833) / Eli Lilly
New P3 trial: ACHIEVE-3: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin (clinicaltrials.gov) - Sep 21, 2023
P3, N=1576, Not yet recruiting, Sponsor: Eli Lilly and Company
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants (clinicaltrials.gov) - Sep 18, 2023
P1, N=120, Recruiting, Sponsor: Novo Nordisk A/S
Patients with T2DM in this study experienced significant reductions in HbA1c within 6 Not yet recruiting --> Recruiting
- || metformin / Generic mfg.
Review, Journal: Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review. (Pubmed Central) - Sep 17, 2023
The 10 GLP-1RAs are exenatide (including exenatide twice daily and once weekly), liraglutide, lixisenatide, dulaglutide, PEX168, semaglutide (subcutaneous and oral semaglutide), tirzepatide and albiglutide...In addition, this study may provide reference and evidence-based medical evidence for clinicians to select GLP-1RAs in patients with T2D and high body mass index (BMI). Based on the NMA results, tirzepatide 15mg and semaglutide 1.0mg may be preferred.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Preclinical, Journal: Oral Semaglutide under Human Protocols and Doses Regulates Food Intake, Body Weight, and Glycemia in Diet-Induced Obese Mice. (Pubmed Central) - Sep 13, 2023
Oral semaglutide with human protocols and doses rapidly reduces blood glucose and food intake and continuously suppresses feeding and weight in DIO mice. This study establishes mice as a model suitable for analyzing the mechanism of anti-obesity/diabetes actions of oral semaglutide.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice (clinicaltrials.gov) - Sep 8, 2023
P=N/A, N=462, Enrolling by invitation, Sponsor: Novo Nordisk A/S
This study establishes mice as a model suitable for analyzing the mechanism of anti-obesity/diabetes actions of oral semaglutide. Trial primary completion date: Jul 2023 --> Mar 2023
- ||||||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: OASIS 2: Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity (clinicaltrials.gov) - Sep 6, 2023
P3, N=201, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: Jul 2023 --> Mar 2023 Active, not recruiting --> Completed
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Oral semaglutide: an OASIS from injectables. (Pubmed Central) - Aug 31, 2023
Active, not recruiting --> Completed No abstract available
- Rybelsus (semaglutide oral) / Novo Nordisk
Trial protocol: Randomized double blind controlled study to investigate disease modifying effect, safety and optimal dose of oral semaglutide tablet for patients with Parkinson () - Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1414;
This study will evaluate safety, efficacy and dosage-effect of oral semaglutide tablet for PD. The trial design including the withdrawal period of study drugs will provide insight into the disease modifying effect of semaglutide, one of GLP-1RAs, against PD.
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
P3 data, Journal: Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. (Pubmed Central) - Aug 28, 2023
P3
Oral semaglutide 25 mg and 50 mg were superior to 14 mg in reducing HbA and bodyweight in adults with inadequately controlled type 2 diabetes. No new safety concerns were identified.
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
P3 data, Journal: Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. (Pubmed Central) - Aug 28, 2023
P3
No new safety concerns were identified. In adults with overweight or obesity without type 2 diabetes, oral semaglutide 50 mg once per day led to a superior and clinically meaningful decrease in bodyweight compared with placebo.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China. (Pubmed Central) - Aug 25, 2023
However, at an annual price of $1,871.9, it was cost-effective compared with dulaglutide, liraglutide, and lixisenatide...However, to achieve cost-effectiveness in comparison to placebo, further cost reduction of oral semaglutide is necessary. The estimated annual cost of $1,711.03 for oral semaglutide demonstrates a more cost-effective option than placebo, highlighting its potential value in the management of T2DM.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: Clinical Trial of Rybelsus (semaglutide) Among Adults with Alcohol Use Disorder (AUD) (clinicaltrials.gov) - Aug 22, 2023
P2, N=135, Recruiting, Sponsor: University of Colorado, Denver
The estimated annual cost of $1,711.03 for oral semaglutide demonstrates a more cost-effective option than placebo, highlighting its potential value in the management of T2DM. Not yet recruiting --> Recruiting
- | Rybelsus (semaglutide oral) / Novo Nordisk
New P4 trial: GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH (clinicaltrials.gov) - Aug 21, 2023
P4, N=125, Not yet recruiting, Sponsor: Massachusetts General Hospital
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants (clinicaltrials.gov) - Aug 18, 2023
P1, N=120, Not yet recruiting, Sponsor: Novo Nordisk A/S
- || Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice (clinicaltrials.gov) - Aug 14, 2023
P=N/A, N=462, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2023 --> Oct 2023
- | Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion date, Real-world evidence, Real-world: NN9924-4645: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice (clinicaltrials.gov) - Aug 14, 2023
P=N/A, N=194, Recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Apr 2023 --> Oct 2023 Trial completion date: Feb 2024 --> May 2024
- || Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion date, Trial primary completion date, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice (clinicaltrials.gov) - Aug 14, 2023
P=N/A, N=194, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: Feb 2024 --> May 2024 Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Apr 2023 --> Dec 2023
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion, Enrollment change: A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People (clinicaltrials.gov) - Aug 14, 2023
P1, N=546, Completed, Sponsor: Novo Nordisk A/S
Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Apr 2023 --> Dec 2023 Active, not recruiting --> Completed | N=404 --> 546
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Oral Semaglutide Induces Loss of Body Fat Mass Without Affecting Muscle Mass in Patients With Type 2 Diabetes. (Pubmed Central) - Aug 14, 2023
Furthermore, the appendicular skeletal muscle index (SMI) defined as appendicular skeletal muscle mass (ASM)/height squared (units; kg/m) was also unchanged. The 24-week treatment with oral semaglutide ameliorated glycemic control with reduction of body fat but not muscle mass in Japanese patients with type 2 diabetes.